Skip to main content

Advertisement

Table 2 Summary of least squares mean (SEM) change from baseline in secondary efficacy endpoints at week 12 (proof-of-concept component; FAS, LOCF)

From: Maraviroc, a chemokine receptor-5 antagonist, fails to demonstrate efficacy in the treatment of patients with rheumatoid arthritis in a randomized, double-blind placebo-controlled trial

  Placebo Maraviroc 300 mg BID Pvalue
ACR components    
   Tender/painful joint count -3.41 (1.19) [n = 33] -4.89 (0.84) [n = 77] 0.294
   Swollen joint count -3.43 (0.95) [n = 33] -3.48 (0.66) [n = 77] 0.966
   Patient's assessment of arthritis pain -6.09 (4.06) [n = 33] -8.30 (2.85) [n = 77] 0.644
   Patient's global assessment of arthritis -6.78 (4.06) [n = 33] -8.55 (2.88) [n = 76] 0.712
   Physician's global assessment of arthritis -0.36 (0.15) [n = 32] -0.49 (0.11) [n = 75] 0.490
   HAQ-DI -0.06 (0.13) [n = 20] -0.18 (0.08) [n = 55] 0.396
SF-36 version 2 (acute)    
   Physical component summary 4.81 (1.65) [n = 19] 3.14 (1.04) [n = 53] 0.344
   Mental component summary 0.61 (2.25) [n = 19] 1.17 (1.41) [n = 53] 0.818
  1. ACR, American College of Rheumatology; BID, twice daily; FAS, full analysis set; HAQ-DI, health assessment questionnaire-disability index; LOCF, last observation carried forward; SEM, standard error of the mean; SF-36, Short Form-36 Health Survey.